RxDoctor Payments Data

Vinay Aakalu, MD

Ophthalmology · Ann Arbor, MINPI 1851598072

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,000 of the $16,170 with a category attached, or 61.8%. Amgen accounts for 98.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $10,820 and has fallen 52.7% since, to $5,122 in 2025. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,170in general payments, 2019–2025

Across 32 payments — averaging $505.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$16K
  • Biotissue Holdings Inc.$129
  • Genentech USA, Inc.$80
$413,265in research payments, 2019–2025

Across 19 payments — averaging $21,751 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$275K
  • Genentech, Inc.$138K

What the payments were for

  • Consulting fees$650%
  • Speaking & faculty fees$10,00062%
  • Travel & lodging$5,58135%
  • Food & beverage$4903%
  • Education$340%

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)30$15,961
Biotissue Holdings Inc.1$129
Genentech USA, Inc.1$80

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,170 in reported general payments places this provider in the 95th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$182,654
Medicare patients
192
Services billed
941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErythromycinErythromycin Base47$538

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →